MedTrace Logo

Prognostic Model for MASLD Related Cirrhosis

NCT07082751 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 228

Last updated 2025-07-24

No results posted yet for this study

Summary

This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months. The primary endpoint was cumulative incidence of liver-related events (including decompensation events, hepatocellular carcinoma, liver transplantation, and liver-related mortality) and all-cause mortality. Secondary endpoints included cumulative incidence of metabolic events and changes in non-invasive fibrosis markers.

Conditions

  • Metabolic Dysfunction Associated Steatotic Liver Disease
  • Compensated Cirrhosis

Interventions

BEHAVIORAL

Lifestyle Guidance

Lifestyle Guidance

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-13
Primary Completion
2030-06-30
Completion
2030-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07082751 on ClinicalTrials.gov